Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 748

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 748
---

Attention: Corporate Secretary

Telephone: (206) 378-0400</div>

If you are a stockholder of Kineta and would like to request documents, please do so by [●], 2025 to receive them before the Kineta special meeting of stockholders. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means.

<div align='center'>496</div>

INDEX TO FINANCIAL STATEMENTS

| TUHURA (F/K/A KINTARA THERAPEUTICS, INC.) FINANCIAL STATEMENTS                                                                           
 Report of Independent Registered Public Accounting Firm                                                                                  
 Consolidated Balance Sheets as of June 30, 2024 and 2023                                                                                 
 Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023                                                         |     | F-2  
 F-4  
 F-5  |
|:-----------------------------------------------------------------------------------------------------------------------------------------|:----|:-----|
| Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended June 30, 2024 and 2023                                     |     | F-6  |
| Consolidated Statements of Cash Flows for the Years Ended June 30, 2024 and 2023                                                         |     | F-7  |
| Notes to the Consolidated Financial Statements                                                                                           |     | F-8  |
| Condensed Consolidated Interim Balance Sheets as of September 30, 2024 and June 30, 2024                                                 |     | F-30 |
| Condensed Consolidated Interim Statements of Operations (Unaudited) for the three months ended September 30, 2024 and 2023               |     | F-31 |
| Condensed Consolidated Interim Statements of Stockholders’ Equity (Deficiency) (Unaudited) for the three months ended September 30, 2024 |     | F-32 |
| Condensed Consolidated Interim Statements of Stockholders’ Equity (Unaudited) for the nine months ended September 30, 2023               |     | F-33 |
| Condensed Consolidated Interim Statements of Cash Flows (Unaudited) for the three months ended September 30, 2024 and 2023               |     | F-34 |
| Notes to Condensed Consolidated Interim Financial Statements (Unaudited)                                                                 |     | F-35 |
| Condensed Consolidated